IDEXX Laboratories, Inc. vs Micron Technology, Inc. — how do they compare? IDEXX Laboratories, Inc. trades at $519.54 (market cap $40.43B), while Micron Technology, Inc. trades at $1,034.65 (market cap $1.17T). The key difference: Micron Technology, Inc. is far larger — about 28.9× IDEXX Laboratories, Inc.'s market cap, and Micron Technology, Inc. pays a 0.06% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Micron Technology, Inc. for 48 Days on average.
| IDXX | MU | |
|---|---|---|
Market Cap | $40.43B | $1.17T |
Volume | 692,164 | 29,425,906 |
Sector | Health | Technology |
52-Week High | $766.68 | $1.21K |
52-Week Low | $504.70 | $181.60 |
Typical Hold Time | 46 Days | 48 Days |
Enterprise Value | $41.32B | $1.13T |
Dividend Yield | — | 0.06% |
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
Micron Technology (MU) trades at $1,026.85, down 5.62% over 24 hours, despite strong fundamental performance. The stock shows bullish technical signals with support at $1,020 and resistance at $1,064. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $33.42 surpassing the $31.77 estimate. Revenue surged to $37.38 billion in 2025 with net income of $8.54 billion, while analyst consensus remains strongly bullish with 82.85% buy ratings and a $1,590 price target.
Outlook remains positive driven by AI memory demand and strategic customer agreements covering 35% of revenue through 2030. Key risks include cyclical memory pricing and potential growth deceleration. The valuation at P/E 13.94 appears reasonable given robust profitability margins and projected 2026 revenue of $133.2 billion. Institutional sentiment supports further upside if execution continues.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →